Cook Medical’s heritage of innovation began decades ago in 1963 when our founder, Bill Cook, developed the fine art of listening—listening to physicians and identifying what they needed to get patients back to living better lives.
Our heritage of collaborating with physician pioneers has led to a legacy of creative, durability-by-design product development in the aortic clinical specialty.
Aortic disease
Aortic disease is currently an incurable, progressive condition with many complexities, which, left untreated, could be life threatening. Since its inception, Cook Medical has been dedicated to providing a complete aortic therapies program, offering a portfolio of endovascular products and services that assist physicians in the management of aortic disease.
The aorta is the main blood vessel that carries blood from the heart to the rest of the body. An aortic aneurysm occurs when a section of the aorta weakens and begins to bulge. This bulge in the aorta is called an aneurysm. An aneurysm can get larger over time as the walls of the aorta become thinner and stretch like a balloon. When an aneurysm occurs in the part of the aorta that runs through the abdomen, it is called an abdominal aortic aneurysm. When an aneurysm occurs in the part of the aorta that runs through the chest, it is called a thoracic aortic aneurysm. Learn more about the causes, symptoms, and treatment options of aortic aneurysms here.
Learn more about the causes, risks and treatment options for aortic dissections.
We are looking forward to this year’s Vascular Annual Meeting from June 15-18 at the Hynes Convention Center in Boston, Mass. Visit the Cook booth Stop by our booth in the Exhibit Hall where you can grab a cup of…
Five key components to providing comprehensive care for patients with aortic dissections. BY SUKGU HAN, MD, MS, AND FERNANDO FLEISCHMAN, MD Aortic dissections make up a significant portion of aortic emergencies that can be rapidly fatal. Time-dependent mortality and morbidity…
A review of this devastating complication including incidence rates after TEVAR for TBAD and the roles of left subclavian artery revascularization, aortic coverage, and cerebrospinal fluid drainage. BY KEAGAN WERNER-GIBBINGS, MS, FRACS, AND BIJAN MODARAI, PhD, FRCS Paraplegia is a…
An overview of advanced imaging methods for the diagnosis and treatment of type B aortic dissection. BY DARREN KLASS, MBChB, MD, MRCS, FCRC, FRCPC Imaging of aortic dissection can be performed both periprocedurally with computed tomography (CT) and intraprocedurally with…
A look at how zone 2 involvement and proximal seal affect TEVAR outcomes for TBAD. BY JOSEPH V. LOMBARDI, MD Zone 2 involvement (ie, disease extending to the aortic segment between the distal margin of left common carotid artery [LCCA]…
A review of the history of the STABLE technique and data from two post hoc comparative analyses comparing these approaches. BY JONATHAN SOBOCINSKI, MD, PhD; DOMINIQUE FABRE, MD; RICHARD AZZAOUI, MD; AND STÉPHAN HAULON, MD, PhD Thoracic endovascular aortic repair…
Recently published data from the STABLE I and STABLE II trials supporting a composite device approach to endovascular treatment of TBAD. BY JOSEPH V. LOMBARDI, MD, AND QING ZHOU, PhD The management of type B aortic dissection (TBAD) has been…
Following FDA approval of Cook Medical’s Zenith Dissection Endovascular System, physicians are beginning to use the new device to improve the lives of and outcomes for patients who suffer from aortic disease. The system gives physicians a less invasive way…
The evidence to guide type B aortic dissection decisions and the aims of repair in acute, subacute, and chronic phases, as well as complicated and uncomplicated cases. BY ATHANASIOS KATSARGYRIS, MD; PABLO MARQUES de MARINO, MD; BALAZS BOTOS, MD; AND…
The 46th annual VEITHsymposium™ kicks off Tuesday, Nov. 19 through Saturday, Nov. 23, in New York City. This esteemed global conference brings vascular surgeons, interventional radiologists, interventional cardiologists, and other vascular specialists together in New York City to hear the…
Nov. 2-4: The VEINS The VEINS (Venous Endovascular INterventional Strategies) is a hands-on, interactive course that focuses on “pulmonary embolism treatment, controversies in VTE management, management of superficial venous disease, and late stage venous disease.” Innovations Summit Monday, Nov. 4,…
What are the goals of treatment in each stage of dissection? It is important to differentiate between acute and chronic. If you talk acute, you have to look at your patient, regulate…
Dr. Jason T. Lee, professor of surgery and program director at Stanford University, has a vested interest in helping educate incoming vascular surgery fellows, residents, and young surgeons in practice. Whether he's giving advice on how to run an efficient…
At Cook, we believe that it is our responsibility to partner with physicians to help improve patient outcomes by developing endovascular grafts that are designed for long-term durability. The now commercially available Zenith Alpha Thoracic Endovascular Graft is the culmination…
The Zenith Alpha™ Thoracic Endovascular Graft is now commercially available in the U.S., following premarket approval from the U.S. Food and Drug Administration in 2015. With a 16-20 Fr delivery system, Zenith Alpha Thoracic was developed to provide…
The years of your fellowship or residency will go by quickly, and it can be difficult to find the time to supplement your formal training. But it can be extremely valuable. Adjunctive training offers the opportunity for cross-specialty skill building,…
This year’s VEITHsymposium® was filled with presentations on new developments in the treatment of aortic disease from the world’s leading physicians. If you weren’t able to be there, here are our top 10 takeaways from the meeting. Don’t skimp on…
In November, Cook is heading to the Wynn Resort in Las Vegas to celebrate the recent approval of Zenith Alpha Thoracic at VIVA15, and we want you to get hands on with the new device! In the Cook booth, you…
The 42nd annual VEITHsymposium is quickly approaching, and we're excited to connect with you in the Cook Pavilion and Educational Suite. This year, you'll be able to relax and connect with colleagues and explore our devices in a whole new…
Boomington, Ind. ─ Cook Medical has received premarket approval from the U.S. Food and Drug Administration (FDA) for its lower-profile Zenith Alpha™ Thoracic Endovascular Graft. Zenith Alpha Thoracic is indicated for the endovascular treatment of patients with isolated lesions of…
Cook is getting ready for the Society for Vascular Surgery's 2015 Vascular Annual Meeting, which will take place June 17-20. Hundreds of physicians from around the world will gather in Chicago for one of the premier meetings for vascular health…
TM Mastracci MD Royal Free London NHS Foundation Trust Assessing the predictive value of a completion angiogram on the long-term durability of EVAR is a task that has only recently been requested of endovascular providers. Now that the endovascular community…
How do we address the chronic nature of aortic disease? That simple question is creating a stir among your vascular colleagues and forcing physicians to ask some tough questions: Should the progression of aortic disease change a physician's approach to…
A Supplement to Endovascular Today, Nov., 2013 sponsored by Cook Medical "The understanding of the progressive nature of aortic disease is evolving; therefore, the approach to endovascular aneurysm repair (EVAR) must also evolve. As a chronic condition that requires long-term…